Kayigil O, Atahan O, Metin A
Urologic Clinics of TCDD Ankara Hospital, Turkey.
Int Urol Nephrol. 1997;29(2):213-20. doi: 10.1007/BF02551344.
Cyproterone acetate was given as monotherapy to 18 patients with advanced prostatic carcinoma at a weekly dose of 300 mg. Progression was observed in all of the patients; median time to progression was 35 months and median survival time was 48 months. Partial response, stabilization, progression and exitus rates by years also showed favourable results, as compared with other forms of therapy in advanced prostatic carcinoma.
醋酸环丙孕酮作为单一疗法给予18例晚期前列腺癌患者，每周剂量为300毫克。所有患者均观察到病情进展；中位进展时间为35个月，中位生存时间为48个月。与晚期前列腺癌的其他治疗形式相比，按年计算的部分缓解、病情稳定、进展和死亡率也显示出良好结果。
